GlassScriptPhysician profile
Scott R Darling
NPI 1487691564
$1,151.32
in general payments reported to CMS, 2019-2025
18 companies · $76.92 in 2025
The $76.92 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $15.85 · 2021: $604 · 2022: $98.73 · 2023: $159 · 2024: $54.40 · 2025: $76.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $279.15 | 2019-2021 | |
| Abbvie INC. | $136.63 | 2021-2024 | Qulipta, Botox |
| Amgen INC. | $124.99 | 2021 | |
| Abbott Laboratories | $120.30 | 2021 | |
| Allergan, INC. | $112.44 | 2021-2022 | |
| Harmony Biosciences LLC | $89.59 | 2021 | |
| Vanda Pharmaceuticals INC. | $48.58 | 2023 | Hetlioz |
| Bioventus LLC | $34.31 | 2025 | Durolane |
| Collegium Pharmaceutical, INC. | $29.13 | 2021-2024 | Xtampza |
| Medtronic, INC. | $25.94 | 2022-2023 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $25.71 | 2025 | Tremfya |
| Boston Scientific Corporation | $20.57 | 2022 | |
| Depuy Synthes Sales INC. | $19.66 | 2021 | |
| Alkermes, INC. | $18.98 | 2023 | Vivitrol |
| Pacira Pharmaceuticals Incorporated | $18.50 | 2023 | Zilretta, Iovera, Exparel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $17.61 | 2024 | Tirosint, Licart |
| Lundbeck LLC | $16.90 | 2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Darling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.